AC Immune Reports Positive ACI-24.060 Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

(24/7 MARKET NEWS) – AC Immune SA (NASDAQ: ACIU) reported, this morning, that the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease (AD). ABATE will now be expanded, as planned, to include individuals with Down syndrome (DS) and to evaluate higher doses in Alzheimer’s patients.

AC Immune opened this morning’s trading at $2.59 and has dropped to $2.42, up $0.08 (+3.42%), on volume of 1.2 million shares traded.

Its 52-week range is $1.68 to $4.93. $2.50 is the key inflection point and, right now, it’s on the wrong side.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist